Drug news
BAX 111 starts Phase III for Von Willebrand Disease
Baxter International Inc. announced initiation of a Phase III clinical trial to evaluate the safety and effectiveness of BAX 111, an investigational recombinant von Willebrand factor (rVWF), for the treatment and prevention of bleeding episodes in patients with von Willebrand disease. This condition is the most common type of inherited bleeding disorder, affecting both men and women, the majority of whom are undiagnosed due to mild symptoms. BAX 111 is the first recombinant von Willebrand product in clinical development.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins